AbbVie Inc. (NYSE: ABBV) and Tentarix Biotherapeutics have unveiled a significant collaboration aimed at pioneering the development of conditionally-active, multi-specific biologics targeting oncology and immunology. This strategic alliance will harness AbbVie’s extensive experience in these fields alongside Tentarix’s groundbreaking Tentacles™ platform.
Tentacles™ represent a novel class of multi-functional, conditionally-active antibody-based biologics engineered to activate immune cells selectively, thereby modulating disease pathways while potentially minimizing safety concerns associated with non-specific immune cell targeting.
Jonathon Sedgwick, Ph.D., Senior Vice President and Global Head of Discovery Research at AbbVie, commented, “Oncology and immunology are pivotal areas of growth for us, where we are actively exploring innovative technologies to deliver groundbreaking therapies that meet the needs of patients. This collaboration underscores our commitment to advancing novel biologics and expanding our portfolios in oncology and immunology with conditionally-active multi-specific molecules.”
Don Santel, Interim Chief Executive Officer of Tentarix Biotherapeutics, expressed enthusiasm about the partnership: “We’re thrilled to collaborate with AbbVie to accelerate the development of cutting-edge, conditionally-active therapeutic programs for patients in need. This collaboration validates our approach to understanding and targeting complex immune interactions driving cancers and inflammatory diseases.”
As per the agreements, Tentarix will receive upfront option payments totaling $64 million from AbbVie for the two programs. AbbVie will obtain an exclusive option to fully acquire the programs following candidate nomination, with additional undisclosed payments for each program.
About AbbVie AbbVie is dedicated to discovering and delivering innovative medicines and solutions to address critical health challenges today and in the future. With a focus on key therapeutic areas including immunology, oncology, neuroscience, and eye care, AbbVie strives to make a meaningful impact on people’s lives. For more information, visit www.abbvie.com and follow @abbvie on social media.
About Tentarix Tentarix is committed to developing first-in-class targeted, multifunctional, conditional therapies across various indications with high unmet medical needs. The company’s focus lies in modulating cell-specific functions while enhancing the safety profile of biologics. Tentarix employs a dedicated team aiming to revolutionize research and development through its understanding of complex immune interactions, discovery of novel human antibodies, and high-throughput screening of conditional multi-specifics. For more information, visit www.tentarix.com.
AbbVie Forward-Looking Statements This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and beliefs and are subject to risks and uncertainties that could cause actual results to differ materially. Factors that could cause or contribute to such differences include, but are not limited to, intellectual property challenges, competition, difficulties in research and development, litigation, and changes in applicable laws and regulations. For additional information on factors that could affect AbbVie’s operations, please refer to AbbVie’s reports filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to update forward-looking statements, except as required by law.
